European Medicines Agency Grants Orphan Drug Designation to Tinengotinib for Biliary Tract Cancer

Tinengotinib has been awarded orphan drug designation from the European Medicines Agency for use in select patients with biliary tract cancer.

Related Keywords

Taiwan ,South Korea ,United States ,America , ,Transthera Sciences Inc ,European Union ,European Medicines Agency ,Transthera Sciences ,North America ,European Medicines ,Dthera Sciences ,Kankeu Fonkoua ,Tinengotinib ,Orphan Drug Designation ,Fema ,Biliary Tract Cancer ,Phase 3 First 308 Study Nct05948475 ,Physicians Choice Of Treatment Vs Tinengotinib ,Fgfr Mutated Cholangiocarcinoma ,